Investigational drug · Phase 2
leronlimab
Also called: PRO 140
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Colorectal Cancer (mCRC).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
30
Any phase or sponsor naming "leronlimab"
First trial start
2025
Jun 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "leronlimab", any sponsor or status.
- Phase 223
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Cancer (mCRC)
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "leronlimab" as an intervention, largest first.
- Leronlimab in Moderately Ill Patients With COVID-19 PneumoniaPivotal-lookingSuspended
Hospital Israelita Albert EinsteinAcademic, hospital or other
NCT04901676 · 612 participants (planned) · Start Sep 9, 2021 · Primary completion Jan 2023
Drug: Leronlimab; Placebo · For: COVID-19 Pneumonia
Sites: Vitória, Brazil; Ipiaú, Brazil; Salvador, Brazil · 27 sites in all
- Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionPivotal-lookingCompleted
CytoDyn, Inc.Industry
NCT02859961 · 562 participants · Start Dec 7, 2016 · Primary completion Sep 16, 2020
Drug: PRO 140 (350 mg); PRO 140 (525 mg) and 1 more · For: HIV
Sites: La Mesa, California; Palm Springs, California; San Francisco, California · 12 sites in all
- Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19Pivotal-lookingCompleted
CytoDyn, Inc.Industry
NCT04347239 · 484 participants · Start Apr 16, 2020 · Primary completion Oct 24, 2021
Drug: Placebo; Leronlimab (700mg) · For: Coronavirus Disease 2019
Sites: Alexander City, Alabama; Fullerton, California; Los Angeles, California · 18 sites in all
- Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane OxygenationPivotal-lookingSuspended
Hospital Israelita Albert EinsteinAcademic, hospital or other
NCT04901689 · 316 participants (planned) · Start Oct 23, 2021 · Primary completion Feb 2023
Drug: Leronlimab; Placebo · For: COVID-19 Pneumonia
Sites: Laranjeiras, Brazil; Ipiaú, Brazil; Salvador, Brazil · 23 sites in all
CytoDyn, Inc.Industry
NCT04521114 · 87 participants · Start Dec 1, 2020 · Primary completion Dec 29, 2021
Drug: Placebo; leronlimab 700 mg and 1 more · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Coronado, California; Maitland, Florida; Miami Lakes, Florida · 7 sites in all
CytoDyn, Inc.Industry
NCT04343651 · 86 participants · Start Apr 1, 2020 · Primary completion Jul 21, 2020
Drug: Placebo; Leronlimab (700mg) · For: Coronavirus Disease 2019
Sites: Los Angeles, California; Palm Springs, California; Rancho Mirage, California · 12 sites in all
- Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral TreatmentRecruiting
Federal University of São PauloAcademic, hospital or other
NCT07903441 · 70 participants (planned) · Start Aug 1, 2026 · Primary completion Jul 31, 2027
Drug: Multiple therapeutic interventions · For: HIV - Human Immunodeficiency Virus
Sites: São Paulo, Brazil
- CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenActive, not recruiting
CytoDyn, Inc.Industry
NCT06699836 · 66 participants · Start Jun 16, 2025 · Primary completion Jan 2028
Drug: 350 mg leronlimab; 700 mg leronlimab and 1 more · For: Metastatic Colorectal Cancer (mCRC)
Sites: Irvine, California; San Francisco, California; Washington D.C., District of Columbia · 7 sites in all
CytoDyn, Inc.Industry
NCT04678830 · 56 participants · Start Mar 1, 2021 · Primary completion Jun 5, 2021
Drug: Placebos; Leronlimab (700mg) · For: Coronavirus Disease 2019
Sites: Aventura, Florida; Gainesville, Georgia
- An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyPivotal-lookingTerminated
CytoDyn, Inc.Industry
NCT05271370 · 56 participants · Start Aug 29, 2017 · Primary completion Jun 20, 2022
Drug: PRO 140 350; PRO 140 525 and 1 more · For: HIV-1-infection
Sites: San Francisco, California
Newest research
PubMed records naming it or its code names, newest first.
- Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV.
Sacha JB, Ordonez T, Pandey S, et al. · Nat Microbiol 2026
- The guanine nucleotide exchange factor Rin-like is a repressor for renal uric acid excretion in human and mouse.
Han C, He C, Hu W, et al. · Sci Transl Med 2026
- An ER stress-responsive RNA rheostat for programmable gene and mRNA therapies.
Ogurlu R, Sanchez EB, Hull JA, et al. · Cell Chem Biol 2026
- Adeno-associated virus gene therapy-mediated CCR5 blockade suppresses virus replication long term in SHIV-infected macaques.
Wu HL, Webb GM, Fuchs SP, et al. · Sci Transl Med 2026
- CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2-CCL2, CCR5-CCL5, CCR4-CCL17/22, CCR6-CCL20, CCR7-CCL19/21.
Bahng I · Front Immunol 2026
- Chemokine receptor type-5: a key regulator of immunity, disease pathogenesis, and emerging therapeutic target.
Bambal V, Kodihalli Basavaraj P, Vanaja K · Inflammopharmacology 2025
Also in development for Metastatic Colorectal Cancer (mCRC)
- JMT101Phase 37 trials
Shanghai JMT-Bio Inc. · Local Advanced or Metastatic NSCLC, Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
- LPM6690176Phase 21 trial
Luye Pharma Group Ltd. · Metastatic Colorectal Cancer (mCRC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.